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Photosensitizers and Radiosensitizers in Dermatology and
Oncology
V. BROCK ER
(psora lens) (Fig. 1) and long-wave DV light of 320 - 380
nm ( V-A)."
S 1\1 1ARY
Two therapeutic modalities are currently of great interest,
namely photo- and radiosensitization. Whereas photo-
sensitizers only function in combination with ultraviolet
(UV) light, radiosensitizers act only in combination with
ionizing radiation. Because of the small UV penetration,
up to a maximum of 0,5 mm, photosensitization can take
place only at the surface of the body, i.e. the skin. Pho-
tosensitizers are applied in dermatology in order to op-
timize and improve the UV therapy of certain diseases
(mainly psoriasis, mycosis fungoides and vitiligo). Radio-
sensitizers lead to an increase in sensitivity of the
hypoxic and therefore radioresistant parts of tumours
against X- and gamma-radiation. With sufficient concen-
tration within the tumour, they can act where the radiation
can reach, even in the deeper parts of the body. They
represent a modern and useful aid to radiation oncology.
Because of neurotoxic effects, however, their practical
use is limited. A short review of the history, mechanisms
of action, application and side-effects of these photo-
and radiosensitizers is presented.
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Two therapeutic rnodalities have currently gained in-
creased importance, namely photosensitization (better
known as photochemotherapy or P VA therapy (psoralen
plus ultraviolet A» and radiosensitization. Both are accom-
plished with chemical compounds, the so-called sensitizer ,
which ideally have no effects themselves, but act only
in combination with radiation, thereby increasing its
effect. Compounds which sensitize the body against DV
light are called photosensitizers, whereas those with the
appropriate property against ionizing radiation are known
as radiosensitizers.
PHOTOSENSITIZATION
The phenomenon of photosen itization has been re-
cognized for a long time. For example, there is the treat-
ment of vitiligo with certain plants in combination with
sunlight, the occurrence of a phytophotodermatitis after
unbathing in meadows, and berlock dermatiti after
the use of certain perfumes. The basic requirement for
these reactions is always the simultaneous presence of
photo ensitizing plant substances, the furocoumarins
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Fig. 1. Structure of the photoseositizers.
As the total penetration depth of DV radiation in the
human body does not exceed 0,5 mm, photosensitizers
can act only at the surface of the body, i.e. in the outer
layers of the skin. owadays this is exploited thera-
peuti ally to a greater extent, since high-intensity DV-A
irradiation facilities permit short exposure times. -
Biochemical Mechanism
The most probable explanation of the biochemical
mechanism is as follows: under the influence of long-
wave V light (365 om) the furocoumarins, for example
-methoxypsoralen (8-MOP), react with the pyrimidine
bases of D A_ for example thymine (Fig. 2). By breaking
open the 5,6 double bond of the thymine on the one hand,
and the 3,4 andlor 4,5 double bond of 8-MOP on the
other hand, a new bond between the photosensitizer and
the D A is established, with the formation of a typical
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C. ring. A one-sided or a double-sided photo-addition i
possible. through which the two adjacent DNA strands
can be cross-linked. As a result of thi interaction between
the p oralen and the D A of dermal and e pecially
epidermal elJs. D TA synthesis and therefore mitosi I
inhibited, a process which is. of course. PUVA dose-
dependent."
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It is obvious that this prin iple is mainly applicable to
skin di ease caused by increased cell proliferation. uch
aporia i and mycosi fungoides. tage III of the latter
in lude ulcerating tumour. The I:onventional therapy of
both disea es consists illfer alia of intensive exposure to
sunlight or U -B irradiation (290 - 320 nm). P VA
therapy is also indicated in cases of vitiligo, although the
exact mechanism of action is still not clear. It is possible
that the desired repigmentation includes stimulation of
melanocyte production.
Technique
In order to achieve optimal photosensitization, -MOP
(20 - 60 mg, according to body weight) is administered
orally 2 hours before every UV-A exposure (peak emission
365 nm). During the initial whole-body exposures, UV-A
doses of approximately I - 5 J Icm' are used. Because of
the development of pigmentation and therefore of increased
resistance, these doses are then increased stepwise. At
first, psoriasis and mycosis fungoide treatments are carried
out four times per week. When patients are completely
symptom-free, i.e. usually after 4 - 8 weeks, treatment
to prevent recurrence is carried out at greater intervals.
If the disease recurs, the frequency of treatment is temp-
orarily increased.'·lo,,, Altogether, the following number
of P VA exposures is required: psoriasis approximately
10 - 30, myco i fungoide 20 - 60. and vitiligo 100 - 300.13
Results
Fig. 2. Photo-addition between psoralen and DNA base.
The result have been good, sometime even ver_
good, and in any case better than those after V -B
irradiation alone (Table I). In more than 900~ of psoriasis
patients there is complete short-term remission. After a
longer time interval, the remission rate is still greater
than 70°:". early all stage I and stage 11 patients suffering
from mycosis fungoides are cured. Among 4 stage III
patients treated, I was cured completely whereas the other
3 had incomplete remission. ]n approximately 75°0 of
vitiligo cases moderate or good repigmentation is attained.
It is obvious that more reliable data will only be available
TABLE I. SUMMARY OF RESULTS OF PUVA TREATMENT
Results
Skin disease and
required PUVA
exposures"
Psoriasis
(10 - 30)
Mycosis fungoides
(20 - 60)
Vitiligo
(100 - 300)
Authors
Parrish et al."
Wolff et aI"
Braun-Falco et al.'
Hofmann et aI'
Konrad et al.'o
Konrad et al.'o
Fitzpatrick et aI'
Parrish et al."
Number of
patients treated
21
152
259
10 (stage I, 11)
15 (stage I, 11)
4 (stage Ill,
Le. tumours)
84'
26
Short-term
remission (wks)
U·)
100
93
91
100
Long-term
remission (mo.)
('1- )
88
70
90
100
25
Replgmentation
moderate to
good
('10)
75
73
Sun exposure Instead of UV·A exposure.
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after greater numbers of patients have been treated.
The applicability of photosensitizers is not limited by
acute side-effects caused by them in combination with
V-A radiation, namely pruritus, nausea and skin irri-
tation, but there is still some uncertainty about possible
carcinogenic late effects. Although it is known that
mutations and cancer are induced mainly by UV
radiation with a wavelength shorter than 320 nm, an
oncogenic effect of PUVA therapy cannot be excluded
with certainty, becau e of the interaction between psoralen
and DNA. At the moment this still overshadows the
application of photochemotherapy.
is why other radiosensitizers are not effective under such
conditions.
Radiosensitizers would be of no practical value if they
sensitized not only the tumour but also the normal tissue.
Because they act exclusively under hypoxic conditions,
which occur only in tumours, a selective effect is guaran-
teed. ]n contrast to photosensitizers, which can act only
at the urface of the body, radiosensitizers are effective in
deeper-lying tumours. A prerequisite for this is, of course,
that these compounds accumulate in the tissue and that
radiation is used with sufficient energy, i.e. with the
necessary penetration depth.
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Fig. 3. Possible mechanism of action of the radiosensitizers.
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Two Effective Compounds
So far, two compounds have proved themselves in this
connection: the rutro-imidazoles, metrorudazoie (Flagyl)
and misonidazole (Ro 07-0582; Fig. 4). They are character-
ized by high efficiency, good accumulation in the tumour,
relatively good compatibility, and low toxjcity. Quanti-
tatively the radiosensitizing effect is expressed through
the so-called enhancement ratio, i.e. the relation of the
radiation dose without sensitizer to the radiation dose
with ensitizer. which gives the same effect (if there i
sensitization, then this ratio is always greater than 1).
Both agents were tested on different biological models and
on all occasions misonidazole proved itself to be the better
radiosensitizer (Table Il).
RADIOSENSITlZATION
For immunological and cell kinetic reasons, more than
99°0 of the cells have to be destroyed to achieve per-
manent cure of solid tumours. However, radiation cannot
be used to an unljmited extent, since the normal tissue
must be protected as much as possible. and this is the
limiting factor. Furthermore, not all tumour cells are
equally radiosensitive. Those with a lesser oxygen content
(up to 50% of experimental tumours) are much more
radioresistant and are often responsible for the failure of
radiotherapy. We have therefore been striving for years
to improve the efficiency of radiotherapy by several
methods, including the use of true radiosensitizers.
The observation that the radiosensitizing effect of a
chemical compound is based on its electron affinity made
the search for suitable sensitizers much easier. It has also
been found that only hypoxic tissue is sensitized to X-
and gamma-radiation. This, as well as the fact that radio-
sensitizers can only function if they are present at the
desired place during irradiation, i.e. that they must be
administered before the exposure, is explained by their
possible mechanism of action (Fig. 3). Because of its
electron affinity, the sensitizer probably competes with
endogenous radio protectors such as glutathione (OSH)
for reaction with the damaged biomolecule. If the sensitizer
succeeds in reacting with the bioradical, i.e. the radio-
protector, and repair is thus excluded, this leads to
stabilization of the lesion.' Tn the presence of oxygen, the
latter is accomplished by the oxygen already present; this
TABLE 11. ENHANCEMENT RATIOS ATIAINED
Enhancement ratio
Hypoxic human skin in vivo Dische et al. 4
(pigmentation)
Dische et al.'
Human tumours in vivo (re- Thomlinson et al."
mission, regrowth) Jentzsch et ai'
Model and criterion
Hypoxic mammalian cells
in vitro (survival)
5 different mouse tumours
in vivo (remission, re-
growth, etc.)
Authors
Asquith et al.'
Asquith et al.'
Several authors cited by
Phillips"
Concentration/dose
Metronidazole Misonidazole of radiosensitizer
1,9 8 mmol/I
2,5 4 mm
1,6 2 1 mg/g
(average) (average)
1,5 0,2 - 0,3 mg/g
(average)
1,1 200 mg/kg
(average)
1,15 80 mg/kg
1,2 4 9
1,5 60 - 80 mg/kg
(estimate)
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Fig. 4. Structure of the radiosensitizers.
Both substances are already in use in radiation treat-
ment of human tumours in various countries, including
South Africa." As a guideline, the treatment scheme of
Jentzsch et al.; who treated (mainly) brain tumours, may
be studied. According to this, approximately 4,5 g
misonidazole is administered orally 3 - 4 hours before
irradiation (tumour dose: 400 rad). During each of the
first 2 weeks, two such fractions are given. Subsequently
five fractions per week are given (each of 170 - 200 rad)
for a total of 3 - 4 weeks. The last treatment week re-
sembles the first one. the total radiation dose to the brain
tumour being 5 500 - 6 000 rad and the total misonidazole
dose being 27 - 30 g. The authors estimate that the en-
hancement ratio per fraction achieved with Ihis treatment
scheme is 1.5. Furthermore, Urtasun er al.'· have shown
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In conclusion, photosensitizers and radiosensitizers arc
important therapeutic aids. As their application in derma-
tology and oncology is relatively new. our knowledge i
increasing daily (incidentally, the photosensitizer -MOP
acts under certain conditions as a radiosensitizer and the
radiosensitizer misonidazole acts as a photosensitizer).""
Perhaps it will soon be possible to define the risks which
at present still exist (late effects of photosensitizers. early
effects of radiosensitizers) and to avoid them.
CO CLUSIO
that after unsuccessful radiation treatment. patients with
brain tumours lived an average of 4,5 months longer
when their tumours had been sensitized with metronidazole.
Because of radiosensitizers. the effective radiation dose
to the tumour is nearly always greater than that actually
administered, so that a greater percentage of tumour
cells is destroyed. thereby either increasing the cure rate
or retarding recurrence.
Despite its promi ing radiosensitizing eflect. however.
administration of misonidazole has led to evere though
reversible polyneuropathies:"" the total misonidazole dose
should not exceed 29 - 30 g. Metronidazole is also said
to be neurotoxic in large doses. so that the radiotherapeutic
us~fulness of these two compounds is unrortunately much
reduced.Metronidazole
(Flagyl)
Imidazole
Misonidazole
(Ro-07-0582 )
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